Protocols - Hemorio

More documents

Recommendations

Info

Cycles 2, 4, 6, 8 - Methotrexate 200mg/m 2 in 2 h, followed by 800mg/m 2 IC in 24h D1 - Leucovorin 25mg/m 2 every 6h start 24h after the conclusion of MTX. Total 8 dosages - Cytarabine 3g/m 2 in 2h every 12h 4 doses D2 and D3 (1g/m 2 in subjects > 60 years old) - Methylprednisolone 50mg every 12h D1 to D3 - G-CSF 300mcg SC starting 24h after the conclusion of each cycle until medullar recovery, and the next cycle can be started CNS prophylaxis MTX IT 12 mg D 2 of each cycle ARA-C IT 100 mg D 8 of each cycle FLAG/IDA Protocol (the same as LMA) ALLOGENIC TRANSPLANT Related allogenic TMO recommended in 1 st RC for ALL adult subjects below 40 years old, irrespective the risk category. Not-related allogenic TMO recommended in 1 st RC for high-risk subjects and < 40 years old with no donor related. IN SECOND REMISSION: All subjects Refractory LLA Alternate cycles scheme of QT - palliative St Jude Week 1 - Cyclophosphamide 300mg/m 2 - Vincristine 1mg/m 2 (maximum 2mg) Week 2 - Cytarabine 300mg/m 2 - VM-26 150mg/m 2 114
NON-B ACUTE LYMPHOID LEUKEMIA AND LYMPHOBLAST LNH (CHILD) Protocol based on Protocol BFM 2002 (version without the application of minimal residual disease for the stratification of the risk group). DIAGNOSIS TESTS: - Full hemogram - Bone marrow aspirated for cytology, cytochemistry, immunophenotype and cytogenetical study. - Lumbar puncture to the diagnosis (cytology and biochemistry) - HLA of subject and brothers (at the high risk). TREATMENT ALGORITHM To the DIAGNOSIS Age 1 – 5 years old and Leuko < 20 mil/mm Age 6 years old or t(9;22) or t(4;11) 3 and Leuko ≥ 20 mil/mm3 Blasts D8 < 1,000/mm and 3 Blasts D8 < 1,000/mm3 Blasts D8 > 1,000/mm3 ↓ ↓ D15 M1 / M2 M3 M1 / M2 M3 ↓ ↓ D33 M1 M2 / M3 M1 M2 / M3 ↓ ↓ RISK GROUP SR IR HR M1 < 5% of blasts M2 > 5% < 25% of blasts M3 > 25% of blasts D15 = 2 weeks PRD + 1 dose VCR / DNB / L-ASP + 2 doses MTX IT Doses decrease: In children below 1 year old or < 10kg. Up to 6 months old 2/3 of the dosage in SC 7-12 months old 3/4 of the dosage in SC ≥ 1 year old 1/1 of the dosage in SC PROTOCOL PHASES: PROTOCOL I: all risk groups Phase 1 PRD VO 60 mg/m 2 divided in 3 doses D1 - 28. FROM D29, REDUCE 50% OF THE DOSAGE, EVERY 3 DAYS VCR - IV 1.5 mg/m 2 D8, 15, 22, 29. MAXIMUM INDIVIDUAL DOSAGE - 2 mg DNR IV 30 mg/m 2 D8, 15, 22, 29 L-ASP IM 10,000 IU /m 2 D12, 15, 18, 22, 25, 29, 31, 33. MTX IT * D 1, 8∗,15, 22∗ e 29 (∗ if CNS positive to the diagnosis) *MTX IT < 1 year old - 6 mg > 1 and < 2 years old - 8 mg > 2 and < 3 years old - 10 mg > 3 years old - 12 mg 115
Page 2 and 3:
PROTOCOLS INSTITUTE OF HAEMATOLOGY
Page 4 and 5:
COORDINATION AND REVISION Clarisse
Page 6 and 7:
SUMMARY: PART I - CLINICAL PROTOCOL
Page 8 and 9:
1.INICIAL CLINICAL EVALUATION SICKL
Page 10 and 11:
TREATMENTO AND IN ADULTS AT ANY AGE
Page 12 and 13:
SPLENECTOMY - INDICATIONS: (1) CHIL
Page 14 and 15:
OUTPATIENT TREATMENT: It is based o
Page 16 and 17:
ASPIRIN AND NSAID PARACETAMOL OPIOI
Page 18 and 19:
CONDUCTION: - Hospitalization - Com
Page 20 and 21:
ONE, TWO-DIMENSIONAL DOPPLER ECHOCA
Page 22 and 23:
Hemianopsia Homonymous deficit of v
Page 24 and 25:
TREATMENT OF CONVULSIVE EPISODES -
Page 26 and 27:
INITIAL ATTENDANCE TO PREGNANT WOME
Page 28 and 29:
- It may occurs acute thoracic synd
Page 30 and 31:
3 Diet with potassium restriction 4
Page 32 and 33:
MICROALBUMINURIA Screening Patients
Page 34 and 35:
RECURRENCE OF PRIAPISM: - Pain Trea
Page 36 and 37:
SPECIAL CARES DEFERASIROX - The use
Page 38 and 39:
TREATAMENT: DRUG Hydroxiurea (hard
Page 40 and 41:
MAJOR AND INTERMIDIATE THALASSEMIA
Page 42 and 43:
HEREDIRATY SPHEROCYTOSIS CLINICAL E
Page 44 and 45:
G6PD DEFICIENCY INITIAL EVALUATION
Page 46 and 47:
LABS EXAMS TO DIAGNOSE APLASTIC ANE
Page 48 and 49:
SELFIMMUNE HEMOLYTIC ANEMIA CONCEPT
Page 50 and 51:
2. Splenectomy: Vaccinate 14 days b
Page 52 and 53:
IMMUNE THROMBOCYTOPENIC PURPURA LAB
Page 54 and 55:
THROMBOTIC THROMBOCYTOPENIC PURPURA
Page 56 and 57:
HEMORRHAGIC SYNDROME INTRODUCTION H
Page 58 and 59:
MULTIDISCIPLINARY FOLLOW-UP OF HEMO
Page 60 and 61:
LYOPHILIZED CONCENTRATES: They are
Page 62 and 63:
TABLE 2: REPLACEMENT THERAPY TO PER
Page 64 and 65: CONDUCTION IN CONFIRMED INTRACRANIA
Page 66 and 67: Severe CET with neurological change
Page 68 and 69: PHARMACOKINETICS OF CLOTTING FACTOR
Page 70 and 71: INHIBITORS CLASSIFICATION The inhib
Page 72 and 73: - Extended surgeries require increa
Page 74 and 75: CLINICAL DIAGNOSIS: According to In
Page 76 and 77: DDAVP TEST The “test dose” must
Page 78 and 79: TREATMENT OF BLEEDING SITUATIONS SI
Page 80 and 81: TABLE 6 - REPLACEMENT THERAPY IN LE
Page 82 and 83: • Primary prophylaxis: controvers
Page 84 and 85: CLINICAL AND LABORATORIAL FOLLOW-UP
Page 86 and 87: MYELODISPLASIC SYNDROME LABORATORIA
Page 88 and 89: If EPO < 500 mU/ml : EPO (8000U 3x/
Page 90 and 91: ACUTE MYELOID LEUKEMIA LABORATORIAL
Page 92 and 93: LMA LMA M3 - non-M3 LMA Protocol LM
Page 94 and 95: Key: Volunteer to aggressive treatm
Page 96 and 97: Acute Promyelocytic Leukemia Transf
Page 98 and 99: BMP LMA IN CHILDREN AND TEENAGERS
Page 100 and 101: Ara-c dose reduction by age: Age in
Page 102 and 103: ATRA RECOMMENDATION: ATRA is starte
Page 104 and 105: - venous hydration - leukapheresis
Page 106 and 107: POLYCYTHEMIA VERA LABORATORIAL TEST
Page 108 and 109: TREATMENT - 2nd LINE - Indicated fo
Page 110 and 111: ACUTE LYMPHOID LEUKEMIA LABORATORIA
Page 112 and 113: RE-INDUCTION Phase I (weeks 1-4) -
Page 116 and 117: PHASE 2 Infusion CPM in 1 hour 1000
Page 118 and 119: CURATIVE RADIOTHERAPY of CNS < 1 ye
Page 120 and 121: CHRONIC LYMPHOCYTIC LEUKEMIA LABORA
Page 122 and 123: fludarabine 25 mg/m VENOUS 2 D1-D3
Page 124 and 125: TRICHOLEUKEMIA LABORATORIAL TESTS -
Page 126 and 127: - age >45 years old - leukocytosis
Page 128 and 129: - Leukemia / T-Cell Lymphoma in Adu
Page 130 and 131: INDICATIONS FOR THE TREATMENT: Symp
Page 132 and 133: 1 st line Chemotherapy R- CHOP (21
Page 134 and 135: CODOX- M/IVAC Cycles 1 and 3 Cyclop
Page 136 and 137: BLOCK A DEXA VO/IV 10 mg /m2 in 3 d
Page 138 and 139: - Surgical treatment is only indica
Page 140 and 141: LEUKEMIA / T-CELLS LYMPHOMA OF THE
Page 142 and 143: HN2 or PUVA (similar to the located
Page 144 and 145: MULTIPLE MYELOMA LABORATORIAL TESTS
Page 146 and 147: RESPONSE CRITERIA Full Response Abs
Page 148 and 149: WALDENSTRON MACROGLOBULINEMIA LABOR
Page 150 and 151: − If HLA-identical related donor
Page 152 and 153: TREATMENT PROTOCOL - ACUTE MYELOID
Page 154 and 155: TREATMENT PROTOCOL - MULTIPLE MYELO
Page 156 and 157: Post-autologous transplantation pro
Page 158 and 159: PART II - TRANSFUSIONAL PROTOCOLS A
Page 160 and 161: PRESERVATION AND CONSERVATION: The
Page 162 and 163: TRANSFUSION OF RED BLOOD CELLS, PLA
Page 164 and 165:
FORMAL CONTRAINDICATIONS TO THE PLA
Page 166 and 167:
1 - TRANSFUSION OF FROZEN FRESH PLA
Page 168 and 169:
COMMUNICATION FORM OF CRYOPRECIPITA
Page 170 and 171:
Volume to be = changed (*) VOLEMIA
Page 172 and 173:
HEMOTHERAPIC PROTOCOL TO FALCIFORM
Page 174 and 175:
5 - TRANSFUSIONAL CONDUCT AT THE SE
Page 176 and 177:
CML - Subjects with symptoms relate
Page 178 and 179:
- Aplastic anemia bearers - HIV pos
Page 180 and 181:
Severe reaction: anaphylactic shock
Page 182 and 183:
- Heart monitoring - Prescribe Furo
Page 184 and 185:
CARES AT THE PLATELETS CONCENTRATE
Page 186 and 187:
ATTACHMENT I - HEMATOLOGICAL CLINIC
Page 188 and 189:
INFECTIOUS SPLENO MEGALIES IMMUNO L
Page 190 and 191:
INVESTIGATION OF HEMORRHAGIC SYNDRO
Page 192 and 193:
INVESTIGATION OF POLYGLOBULIAS: POL
Page 194 and 195:
ATTACHMENT III - HEMATOLOGY SPECIAL
Page 196 and 197:
IMMUNOPHENOTYPE PROFILE OF THE ACUT
Page 198 and 199:
ATTACHMENT IV - PAIN APPROACH ROUTI
Page 200 and 201:
If it is prescribed for more than 1
Page 202 and 203:
HOW TO PRESCRIBE OPIOID: SPECIAL CA
Page 204 and 205:
SPECIFICITIES OF EACH OPIATE (cont
Page 206 and 207:
METHADONE Intravenous (*) Oral path
Page 208 and 209:
Psychic Dependence or “addiction
Page 210 and 211:
CROSS TOLERANCE - The subject must
Page 212 and 213:
ATTACHMENT V - CHEMOTHERAPY SUBJECT
Page 214 and 215:
ATTACHMENT VII - IRON CHELATION GEN
Page 216 and 217:
10. G N N - DFP DFP-100 mg/kg/day d
Page 218 and 219:
ATTACHMENT VIII - SEDATION IN CHILD
Page 220 and 221:
224 NOTES _________________________
Page 222 and 223:
224 NOTES _________________________
Page 224:
Expresso Gráfica e Editora Ltda-me
show all

Protocols - Hemorio

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?